Recurrent Endometrial Cancer
Oncology
Prevalence
58.0 / 100K
Incidence
28.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| imgn151 | ImmunoGen, Inc. (IMGN) |
Frequently asked questions
How many drugs are in development for Recurrent Endometrial Cancer?
BioSniper tracks 1 drug in development for Recurrent Endometrial Cancer across 1 company.
How many clinical trials target Recurrent Endometrial Cancer?
There are 1 clinical trial targeting Recurrent Endometrial Cancer tracked by BioSniper.
What is the prevalence of Recurrent Endometrial Cancer?
The estimated prevalence of Recurrent Endometrial Cancer is approximately 58.0 per 100,000 population.
Deep-dive into Recurrent Endometrial Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis